Oric Pharmaceuticals (ORIC) Price & Analysis

Compare

494 Followers

ORIC Stock Chart & Stats

$13.45

-$0.67(-7.21%)

At close: Jan 08 4:00 PM EST

$13.45

-$0.67(-7.21%)

Day’s Range― - ―

52-Week Range$3.90 - $14.93

Previous CloseN/A

Volume181.02K

Average Volume (3M)1.47M

Market Cap

$1.35B

Enterprise Value$1.32B

Total Cash (Recent Filing)$281.49M

Total Debt (Recent Filing)$11.55M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

May 11, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding100,358,240

10 Day Avg. Volume1,706,876

30 Day Avg. Volume1,472,987

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-6.30

Enterprise Value/Market Cap0.98

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.12K

Enterprise Value/Ebitda-9.86

Forecast

1Y Price Target

$20.70

Price Target Upside53.90% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst Endorsement And Valuation UpsideAnalyst reiteration of a Buy rating and an increased price target reflects confidence in clinical progress for the prostate cancer and lung cancer programs and can bolster investor sentiment.

Brain‑penetrant Lung Cancer DataEnozertinib is designed to penetrate the brain and has shown early systemic and intracranial responses in patients with EGFR mutation‑driven lung cancer, potentially addressing a treatment gap that could differentiate the program from peers.

Dose Optimization And Registrational PathwayProvisional recommended doses for ORIC-944 support a dose‑optimization study whose results are intended to inform initiation of a registrational Phase Three trial in metastatic castration‑resistant prostate cancer.

Bears Say

Intensifying Competitive LandscapeMultiple peer programs and an existing leading therapy in the same first‑line patient group increase competitive pressure and could limit enozertinib's future market share.

Narrowed Indication And Revenue RiskDiscontinuation of development in a separate mutation subgroup reduces the number of potential indications and narrows the drug's overall commercial opportunity.

Tolerability And Durability ConcernsA notable frequency of dose reductions and several unconfirmed responses raise questions about enozertinib's tolerability profile and the durability of observed clinical benefits.

Oric Pharmaceuticals News

Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23...

7d ago

ORIC

Oric Pharmaceuticals price target raised to $17 from $16 at Citi

Citi raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $17 from $16 and keeps a Buy...

7d ago

ORIC

Oric Pharmaceuticals reports Q4 EPS (30c), consensus (37c)

“2025 was a transformational year for ORIC highlighted by clinical data that further demonstrated the potential best-in-class profiles...

8d ago

ORIC

Oric Pharmaceuticals expects cash to fund operations into 2H 2028

Cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025, which includes net proceeds of...

8d ago

ORIC

Oric Pharmaceuticals announces upcoming milestones

ORIC anticipates the following upcoming milestones: Rinzimetostat in mCRPC: 1Q 2026: Combination dose optimization data with AR inhibitor;...

8d ago

ORIC

Oric Pharmaceuticals Launches New 2026 ATM Share Program

Oric Pharmaceuticals ( ($ORIC) ) just unveiled an update. On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into...

8d ago

ORIC

Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks

Cancer remains one of the world’s deadliest challenges. Second only to heart disease, it claims one in every...

1M ago

OLMA

ORIC

ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on ORIC stock, giving a Buy rating today....

2M ago

ORIC

Oric Pharmaceuticals provides operational highlights for 2025

ORIC Pharmaceuticals (ORIC) announced operational highlights for 2025 and anticipated upcoming milestones. Key highlights includes: Announced rinzimetostat Phase...

2M ago

ORIC

3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy...

2M ago

OLMA

ORIC

Oric Pharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals (ORIC) with an Overweight rating and $22 price...

2M ago

ORIC

Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

Oric Pharmaceuticals ( ($ORIC) ) has issued an update. On December 6, 2025, Oric Pharmaceuticals presented an update...

3M ago

ORIC

Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo

Wells Fargo raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $19 and keeps an...

3M ago

ORIC

Buy Rating for Oric Pharmaceuticals: Enozertinib’s Promising Efficacy and Strategic Value

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ORIC stock, giving a Buy rating on...

3M ago

ORIC

ORIC FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?

Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.93 in the past 12 months.

What is Oric Pharmaceuticals’s market cap?

Oric Pharmaceuticals’s market cap is $1.35B.

When is Oric Pharmaceuticals’s upcoming earnings report date?

Oric Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 69 days.

How were Oric Pharmaceuticals’s earnings last quarter?

Oric Pharmaceuticals released its earnings results on Feb 23, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.04.

Is Oric Pharmaceuticals overvalued?

According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals does not currently pay dividends.

What is Oric Pharmaceuticals’s EPS estimate?

Oric Pharmaceuticals’s EPS estimate is -0.34.

How many shares outstanding does Oric Pharmaceuticals have?

Oric Pharmaceuticals has 100,358,240 shares outstanding.

What happened to Oric Pharmaceuticals’s price movement after its last earnings report?

Oric Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 14.603%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals?

Currently, no hedge funds are holding shares in ORIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oric Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-41.27%

Trailing 12-Months

Asset Growth

48.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals (ORIC) Earnings & Revenues

Historic Earnings Reports

ORIC Stock 12 Month Forecast

Average Price Target

$20.70

▲(53.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.16,12.224615384615385,13.28923076923077,14.353846153846153,15.418461538461539,16.483076923076922,17.54769230769231,18.61230769230769,19.676923076923075,20.74153846153846,21.806153846153848,22.87076923076923,23.935384615384613,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.16,11.893846153846154,12.627692307692307,13.361538461538462,14.095384615384615,14.829230769230769,15.563076923076924,16.29692307692308,17.03076923076923,17.764615384615382,18.498461538461537,19.232307692307693,19.966153846153844,{"y":20.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.16,11.455384615384615,11.750769230769231,12.046153846153846,12.341538461538462,12.636923076923077,12.932307692307692,13.227692307692308,13.523076923076923,13.818461538461538,14.113846153846154,14.409230769230769,14.704615384615384,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 62, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >